keyword
MENU ▼
Read by QxMD icon Read
search

edss

keyword
https://www.readbyqxmd.com/read/29792188/health-related-quality-of-life-in-multiple-sclerosis-temperament-outweighs-edss
#1
S Salhofer-Polanyi, F Friedrich, S Löffler, P S Rommer, A Gleiss, R Engelmaier, F Leutmezer, B Vyssoki
BACKGROUND: The influence of personality on health-related quality of life in patients with multiple sclerosis has been the focus of previous studies showing that introversion and neuroticism were related with reduced health related quality of life. However, no data exist on the impact of temperament on quality of life in this patient group. METHODS: Between April 2014 and March 2016 139 multiple sclerosis patients were recruited from a specialized outpatient clinic of the general hospital of Vienna...
May 23, 2018: BMC Psychiatry
https://www.readbyqxmd.com/read/29789706/short-segment-transverse-myelitis-lesions-in-a-cohort-of-latin-american-patients-with-neuromyelitis-optica-spectrum-disorders
#2
Edgar Carnero Contentti, Vanessa Daccach Marques, Ibis Soto de Castillo, Verónica Tkachuk, Amilton Antunes Barreira, Elizabeth Armas, Edson Chiganer, Camila de Aquino Cruz, José Luis Di Pace, Javier Pablo Hryb, Carolina Lavigne Moreira, Carmen Lessa, Omaira Molina, Mónica Perassolo, Arnoldo Soto, Alejandro Caride
STUDY DESIGN: Multicenter retrospective study. OBJECTIVES: The aim was to determine the frequency and magnetic resonance imaging (MRI) features of short-segment transverse myelitis (STM) in patients with neuromyelitis optica spectrum disorders (NMOSD) during a myelitis attack. SETTING: Latin American diagnostic centres (Neuroimmunology Unit). A multicenter study from Argentina, Brazil and Venezuela was performed. METHODS: Seventy-six patients with NMOSD were included...
May 22, 2018: Spinal Cord
https://www.readbyqxmd.com/read/29785523/efficacy-and-safety-of-rituximab-in-relapsing-and-progressive-multiple-sclerosis-a-hospital-based-study
#3
Carmen Alcalá, F Gascón, F Pérez-Miralles, S Gil-Perotín, A Navarré, I Boscá, F Coret, B Casanova
INTRODUCTION: Rituximab is considered as a potential therapeutic option in relapsing-remitting (RRMS) and progressive forms (PMS) of multiple sclerosis (MS). OBJECTIVE: To investigate the effectiveness and safety of rituximab in MS. PATIENTS AND METHODS: Observational study of effectiveness (clinical and radiological) and safety of rituximab in RRMS and PMS. RESULTS: A total of 90 rituximab-treated patients were collected: 31 RRMS and 59 PMS All patients had an active disease despite standard treatment...
May 21, 2018: Journal of Neurology
https://www.readbyqxmd.com/read/29783240/-effect-of-preventive-treatment-on-cognitive-performance-in-patients-with-multiple-sclerosis
#4
Maria S Shorobura
OBJECTIVE: Introduction: cognitive, emotional and psychopathological changes play a significant role in the clinical picture of multiple sclerosis and influence the effectiveness of drug therapy, working capacity, quality of life, and the process of rehabilitation of patients with multiple sclerosis. The aim: investigate the changes in cognitive function in patients with multiple sclerosis, such as information processing speed and working memory of patients before and after treatment with immunomodulating drug...
2018: Wiadomości Lekarskie: Organ Polskiego Towarzystwa Lekarskiego
https://www.readbyqxmd.com/read/29781383/preferential-spinal-cord-volume-loss-in-primary-progressive-multiple-sclerosis
#5
Charidimos Tsagkas, Stefano Magon, Laura Gaetano, Simon Pezold, Yvonne Naegelin, Michael Amann, Christoph Stippich, Philippe Cattin, Jens Wuerfel, Oliver Bieri, Till Sprenger, Ludwig Kappos, Katrin Parmar
BACKGROUND: Little is known on longer term changes of spinal cord volume (SCV) in primary progressive multiple sclerosis (PPMS). OBJECTIVE: Longitudinal evaluation of SCV loss in PPMS and its correlation to clinical outcomes, compared to relapse-onset multiple sclerosis (MS) subtypes. METHODS: A total of 60 MS age-, sex- and disease duration-matched patients (12 PPMS, each 24 relapsing-remitting (RRMS) and secondary progressive MS (SPMS)) were analysed annually over 6 years of follow-up...
May 1, 2018: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/29778042/reliability-and-validity-of-the-dymus-questionnaire-for-the-assessment-of-dysphagia-in-multiple-sclerosis-greek-version-and-proposed-modification
#6
Athanasia Printza, Maria Kalaitzi, Christos Bakirtzis, Ioannis Nikolaidis, Hariklia Proios, Nikolaos Grigoriadis
BACKGROUND: Recent research confirmed that at least a third of people with multiple sclerosis (MS) are suffering from swallowing difficulties. Dysphagia is associated with significant morbidity and mortality, and has profound impact on physical ability and quality of life. Dysphagia related complications can be prevented through an effective screening protocol. The Dysphagia in Multiple Sclerosis (DYMUS) questionnaire is the first dysphagia questionnaire developed specifically for patients with MS...
May 10, 2018: Multiple Sclerosis and related Disorders
https://www.readbyqxmd.com/read/29778041/the-efficacy-of-vitamin-d-in-multiple-sclerosis-a-meta-analysis
#7
REVIEW
Chao Zheng, Liang He, Lingling Liu, Jie Zhu, Tao Jin
BACKGROUND: Multiple sclerosis (MS) is a chronic inflammatory demyelination disorder in the central nervous system (CNS) leading to a high level of neurological disability. The pathogenesis of MS remains largely unknown, which explains the lack of significant efficacy of therapy in MS. Vitamin D deficiency is widely considered to be an environmental risk factor for MS. Many studies investigating the therapeutic effects of vitamin D on MS have been applied. The objective of this systematic review and meta-analysis was to evaluate the effectiveness of vitamin D in MS patients...
May 12, 2018: Multiple Sclerosis and related Disorders
https://www.readbyqxmd.com/read/29768414/adipose-derived-mesenchymal-stem-cells-admsc-for-the-treatment-of-secondary-progressive-multiple-sclerosis-a-triple-blinded-placebo-controlled-randomized-phase-i-ii-safety-and-feasibility-study
#8
Oscar Fernández, Guillermo Izquierdo, Victoria Fernández, Laura Leyva, Virginia Reyes, Miguel Guerrero, Antonio León, Carlos Arnaiz, Guillermo Navarro, Maria Dolores Páramo, Antonio De la Cuesta, Bernat Soria, Abdelkrim Hmadcha, David Pozo, Rafael Fernandez-Montesinos, Maria Leal, Itziar Ochotorena, Patricia Gálvez, Maria Angeles Geniz, Francisco Javier Barón, Rosario Mata, Cristina Medina, Carlos Caparrós-Escudero, Ana Cardesa, Natividad Cuende
BACKGROUND: Currently available treatments for secondary progressive multiple sclerosis(SPMS) have limited efficacy and/or safety concerns. Adipose-mesenchymal derived stem cells(AdMSCs) represent a promising option and can be readily obtained using minimally invasive procedures. PATIENTS AND METHODS: In this triple-blind, placebo-controlled study, cell samples were obtained from consenting patients by lipectomy and subsequently expanded. Patients were randomized to a single infusion of placebo, low-dose(1x106cells/kg) or high-dose(4x106cells/kg) autologous AdMSC product and followed for 12 months...
2018: PloS One
https://www.readbyqxmd.com/read/29766930/measurement-of-the-permeability-perfusion-and-histogram-characteristics-in-relapsing-remitting-multiple-sclerosis-using-dynamic-contrast-enhanced-mri-with-extended-tofts-linear-model
#9
Ping Yin, Hua Xiong, Yi Liu, Shambhu K Sah, Chun Zeng, Jingjie Wang, Yongmei Li, Nan Hong
Objective: To investigate the application value of using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) with extended Tofts linear model for relapsing-remitting multiple sclerosis (RRMS) and its correlation with expanded disability status scale (EDSS) scores and disease duration. Materials and Methods: Thirty patients with multiple sclerosis (MS) underwent conventional magnetic resonance imaging (MRI) and DCE-MRI with a 3.0 Tesla MR scanner. An extended Tofts linear model was used to quantitatively measure MR imaging biomarkers...
May 2018: Neurology India
https://www.readbyqxmd.com/read/29761738/emsqol-29-prospective-validation-of-the-abbreviated-electronic-version-of-msqol-54
#10
Rosalba Rosato, Silvia Testa, Antonio Bertolotto, Francesco Scavelli, Ambra M Giovannetti, Paolo Confalonieri, Francesco Patti, Clara Grazia Chisari, Alessandra Lugaresi, Erika Pietrolongo, Maria Grazia Grasso, Ilaria Rossi, Anna Toscano, Barbara Loera, Andrea Giordano, Alessandra Solari
BACKGROUND: We recently devised a shortened version of the 54-item Multiple Sclerosis Quality of Life (MSQOL-54) in paper (MSQOL-29, consisting of 25 items forming 7 subscales and 4 single items, and one filter question for 3 'sexual function' items) and electronic format (eMSQOL-29). OBJECTIVES: To prospectively assess eMSQOL-29 psychometric properties, acceptability/equivalence versus MSQOL-29. METHODS: Multiple sclerosis (MS) patients ( n = 623; Expanded Disability Status Scale (EDSS) range 0...
May 1, 2018: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/29761737/predictive-validity-of-neda-in-the-16-and-21-year-follow-up-from-the-pivotal-trial-of-interferon-beta-1b
#11
Douglas S Goodin, Anthony T Reder, Anthony L Traboulsee, David Kb Li, Dawn Langdon, Gary Cutter, Stuart Cook, Timothy O'Donnell, Marcelo Kremenchutzky, Joel Oger, Ralf Koelbach, Christoph Pohl, Eva-Maria Wicklein
BACKGROUND: Long-term follow-up from the randomized trial of interferon beta-1b (IFNB-1b) permitted the assessment of different definitions of no evidence of disease activity (NEDA) for predicting long-term outcome in multiple sclerosis (MS). OBJECTIVE: To examine the predictive validity of different NEDA definitions. METHODS: Predictive validity for negative disability outcomes (NDOs) at 16 years and survival at 21 years post-randomization were assessed...
May 1, 2018: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/29761736/treating-neuromyelitis-optica-with-azathioprine-20-year-clinical-practice
#12
Denis Bernardi Bichuetti, Marília Mamprim de Moraes Perin, Nilton Amorim de Souza, Enedina Maria Lobato de Oliveira
BACKGROUND: Neuromyelitis optica leads to severe disability. Preventive treatment includes steroids and immunosuppressants, and indications are based on retrospective and observational studies. METHODS: We analyzed 158 patients with neuromyelitis optica regarding disease course, prognostic factors, and treatment response to azathioprine, a widely available low-cost drug. Disability accumulation was used as an endpoint to treatment response. RESULTS: Eight patients with monophasic and 150 with relapsing disease with a median 7 years of disease duration and 4...
May 1, 2018: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/29759135/the-levels-of-soluble-forms-of-cd21-and-cd83-in-multiple-sclerosis
#13
Sajad Karampoor, Hamid Zahednasab, Masoud Etemadifar, Hossein Keyvani
Multiple Sclerosis (MS) is a neuroinflammatory disease of the central nervous system (CNS) in which immune system plays a crucial role in progression of the disease. An enormous amount of research has been shown that immune mediators such as cytokines and chemokines are the culprits of MS propagation suggesting that modulation of such molecules may pave the path to hinder the disease development. It has been shown that both CD21 and CD83 contribute to the resolution of inflammation occurred in MS. CD21 and CD83 have also been ascribed to Epstein Barr virus (EBV) infection (the prime suspect of MS causality) and the levels of vitamin D, respectively...
July 15, 2018: Journal of Neuroimmunology
https://www.readbyqxmd.com/read/29758118/hemostasis-biomarkers-in-multiple-sclerosis
#14
Nicole Ziliotto, Francesco Bernardi, Dejan Jakimovski, Marcello Baroni, Giovanna Marchetti, Niels Bergsland, Deepa P Ramasamy, Bianca Weinstock-Guttman, Ferdinand Schweser, Paolo Zamboni, Murali Ramanathan, Robert Zivadinov
OBJECTIVE: To investigate the plasma levels of hemostasis components in multiple sclerosis (MS) and their association with clinical and MRI outcomes. METHODS: We studied 138 MS patients (85 with relapsing-remitting, RR-MS and 53 with progressive, P-MS) with mean age of 54 years; 72.5% female; median EDSS 3.5; mean disease duration 21 years) and 42 age- and sex-matched healthy individuals (HI). All subjects were examined with 3T MRI and clinical examinations. Plasma levels of hemostasis factors (procoagulant, factor XII, FXII) and inhibitors (tissue factor pathway inhibitor (TFPI), thrombomodulin (TM), heparin cofactor II (HCII), disintegrin-like and metalloprotease with thrombospondin type 1 motif 13 (ADAMTS13), and plasminogen activator inhibitor 1 (PAI-1) were evaluated by magnetic Luminex assays and ELISA...
May 14, 2018: European Journal of Neurology: the Official Journal of the European Federation of Neurological Societies
https://www.readbyqxmd.com/read/29758075/effectiveness-and-safety-of-rituximab-in-multiple-sclerosis-an-observational-study-from-southern-switzerland
#15
Barbara Scotti, Giulio Disanto, Rosaria Sacco, Marilu' Guigli, Chiara Zecca, Claudio Gobbi
BACKGROUND: Despite positive results from phase II and observational studies, Rituximab (RTX) is not currently approved for multiple sclerosis (MS) treatment and can only be used off-label. OBJECTIVE: To characterize MS patients treated with RTX and investigate its effectiveness and safety in a clinical practice setting. METHODS: Observational analysis of data collected from MS patients at the Neurocenter of Southern Switzerland. Relapses, EDSS worsening, MRI lesion accrual and "evidence of disease activity" (EDA) status were described by Cox regression...
2018: PloS One
https://www.readbyqxmd.com/read/29753215/expiratory-and-phonation-times-as-measures-of-disease-severity-in-patients-with-multiple-sclerosis-a-case-control-study
#16
Sara Nordio, Evanthia Bernitsas, Francesca Meneghello, Katie Palmer, Maria Rosaria Stabile, Laura Dipietro, Arianna Di Stadio
BACKGROUND: Speech disorders are common in patients with Multiple Sclerosis (MS). They can be assessed with several methods, which are however expensive, complex, and not easily accessible to physicians during routine clinic visits. This study aimed at measuring maximum phonation times, maximum expiratory times, and articulation abilities scores in patients with MS compared to healthy subjects and at investigating if any of these parameters could be used as a measure of MS progression...
April 21, 2018: Multiple Sclerosis and related Disorders
https://www.readbyqxmd.com/read/29751787/predictive-value-of-early-magnetic-resonance-imaging-measures-is-differentially-affected-by-the-dose-of-interferon-beta-1a-given-subcutaneously-three-times-a-week-an-exploratory-analysis-of-the-prisms-study
#17
Anthony Traboulsee, David K B Li, Mark Cascione, Juanzhi Fang, Fernando Dangond, Aaron Miller
BACKGROUND: On-treatment magnetic resonance imaging lesions may predict long-term clinical outcomes in patients receiving interferon β-1a. This study aimed to assess the effect of active T2 and T1 gadolinium-enhancing (Gd+) lesions on relapses and 3-month confirmed Expanded Disability Status Scale (EDSS) progression in the PRISMS clinical trial. METHODS: Exploratory analyses assessed whether active T2 and T1 Gd + lesions at Month 6, or active T2 lesions at Month 12, predicted clinical outcomes over 4 years in PRISMS...
May 11, 2018: BMC Neurology
https://www.readbyqxmd.com/read/29746722/pharmacometric-analysis-of-the-relationship-between-absolute-lymphocyte-count-and-expanded-disability-status-scale-and-relapse-rate-efficacy-end-points-in-multiple-sclerosis-trials
#18
A M Novakovic, A Thorsted, E Schindler, S Jönsson, A Munafo, M O Karlsson
The aim of this work was to assess the relationship between the absolute lymphocyte count (ALC), and disability (as measured by the Expanded Disability Status Scale [EDSS]) and occurrence of relapses, 2 efficacy endpoints, respectively, in patients with remitting-relasping multiple sclerosis. Data for ALC, EDSS, and relapse rate were available from 1319 patients receiving placebo and/or cladribine tablets. Pharmacodynamic models were developed to characterize the time course of the endpoints. ALC-related measures were then evaluated as predictors of the efficacy endpoints...
May 10, 2018: Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/29743290/cerebrospinal-fluid-immunoglobulin-light-chain-ratios-predict-disease-progression-in-multiple-sclerosis
#19
Emma Rathbone, Lindsay Durant, James Kinsella, Antony R Parker, Ghaniah Hassan-Smith, Michael R Douglas, S John Curnow
OBJECTIVE: To determine whether the ratio of cerebrospinal fluid (CSF) immunoglobulin kappa to lambda light chains at time of multiple sclerosis (MS) diagnosis predicts disease progression and whether this was intrinsic to CSF plasmablasts. METHODS: CSF and peripheral blood were obtained from patients undergoing elective diagnostic lumbar puncture and included clinically isolated syndrome (CIS) (n=43), relapsing remitting MS (RRMS; n=50), primary progressive MS (PPMS; n=20) and other neurological disease controls, both inflammatory (ONID; n=23) and non-inflammatory (OND; n=114)...
May 9, 2018: Journal of Neurology, Neurosurgery, and Psychiatry
https://www.readbyqxmd.com/read/29731712/baseline-brain-activity-changes-in-patients-with-single-and-relapsing-optic-neuritis
#20
Zhuoqiong Ren, Yaou Liu, Kuncheng Li, Yunyun Duan, Huang Jing, Peipeng Liang, Zheng Sun, Xiaojun Zhang, Bei Mao
Purpose : To investigate spontaneous brain activity amplitude alterations in single and relapsing optic neuritis (sON and rON, respectively) and their relationships with clinical variables. Methods : In total, 42 patients with sON, 35 patients with rON and 50 healthy volunteers were recruited. Resting-state functional Magnetic Resonance Imaging (rs-fMRI) scans were acquired for all participants and compared to investigate the changes in the amplitude of low-frequency fluctuations (ALFFs) among the three groups...
2018: Frontiers in Human Neuroscience
keyword
keyword
84088
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"